Publicaciones (117) Publicaciones en las que ha participado algún/a investigador/a

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  3. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  4. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

    Oncologist, Vol. 28, Núm. 6, pp. 501-509

  5. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis

    Future Oncology, Vol. 19, Núm. 12, pp. 819-828

  6. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology

  7. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    Journal of Clinical Oncology, Vol. 41, Núm. 18, pp. 3339-3351

  8. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

    European Urology Open Science

  9. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3556-3564